UBS AM Portfolio holdings
UBS Asset Management (UBS AM), a division of UBS Group AG with origins tied to the bank’s founding in 1862, is headquartered in Zurich, Switzerland, and manages hundreds of billions in assets for institutional, intermediary, and wealth management clients globally. Specializing in a broad range of investment strategies—including equities, fixed income, multi-asset, alternatives, and sustainable investing—UBS AM leverages the firm’s extensive research capabilities and global network to deliver tailored solutions. Known for its focus on risk management and innovation, it offers products like ETFs, index funds, and private market investments, catering to diverse needs from pension funds to high-net-worth individuals. As part of UBS’s broader ecosystem, UBS AM combines Swiss precision with a commitment to ESG principles, solidifying its position as a leader in the asset management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$438M |
| 2 |
Lockheed Martin
LMT
|
+$402M |
| 3 |
TAL Education Group
TAL
|
+$294M |
| 4 |
Microsoft
MSFT
|
+$269M |
| 5 |
Wells Fargo
WFC
|
+$235M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Mastercard
MA
|
+$384M |
| 2 |
Adobe
ADBE
|
+$372M |
| 3 |
Veeva Systems
VEEV
|
+$342M |
| 4 |
Thermo Fisher Scientific
TMO
|
+$289M |
| 5 |
Global Payments
GPN
|
+$287M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 25.1% |
| 2 | Consumer Discretionary | 13.57% |
| 3 | Healthcare | 12.46% |
| 4 | Financials | 11.55% |
| 5 | Communication Services | 9.78% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1901
Lakeland Financial Corp
LKFN
$1.52B
| $1.07M | ﹤0.01% |
19,994
+3,288
| +20% | +$167K |
|
1902
Rigel Pharmaceuticals
RIGL
$778M
| $1.07M | ﹤0.01% |
30,582
+21,087
| +222% | +$610K |
|
1903
Employers Holdings
EIG
$881M
| $1.07M | ﹤0.01% |
33,150
| – | – |
|
1904
Beam Therapeutics
BEAM
$2.82B
| $1.06M | ﹤0.01% |
+13,038
| New | +$641K |
|
1905
NBT Bancorp
NBTB
$2.73B
| $1.06M | ﹤0.01% |
33,127
| – | – |
|
1906
Primoris Services
PRIM
$4.35B
| $1.06M | ﹤0.01% |
38,472
| – | – |
|
|
PGTI
1907
DELISTED
PGT, Inc.
PGTI
| $1.06M | ﹤0.01% |
52,162
| – | – |
|
1908
CTS Corp
CTS
$1.85B
| $1.06M | ﹤0.01% |
30,877
+2,950
| +11% | +$87.3K |
|
1909
Southside Bancshares
SBSI
$953M
| $1.06M | ﹤0.01% |
34,093
| – | – |
|
1910
Travere Therapeutics
TVTX
$5.74B
| $1.05M | ﹤0.01% |
38,685
| – | – |
|
1911
Enerpac Tool Group
EPAC
$1.89B
| $1.05M | ﹤0.01% |
46,589
| – | – |
|
|
DENN
1912
DELISTED
Denny's
DENN
| $1.05M | ﹤0.01% |
71,720
| – | – |
|
|
ALEX
1913
DELISTED
Alexander & Baldwin
ALEX
| $1.05M | ﹤0.01% |
60,985
+11,168
| +22% | +$163K |
|
|
GES
1914
DELISTED
Guess Inc
GES
| $1.05M | ﹤0.01% |
46,252
-8,604
| -16% | -$136K |
|
|
IMGN
1915
DELISTED
Immunogen Inc
IMGN
| $1.04M | ﹤0.01% |
161,846
| – | – |
|
1916
nLIGHT
LASR
$2.88B
| $1.04M | ﹤0.01% |
31,949
-3,268
| -9% | -$92.5K |
|
1917
BioLife Solutions
BLFS
$1.69B
| $1.04M | ﹤0.01% |
+26,100
| New | +$890K |
|
1918
Ocular Therapeutix
OCUL
$2.03B
| $1.04M | ﹤0.01% |
+50,137
| New | +$745K |
|
1919
Westamerica Bancorp
WABC
$1.35B
| $1.04M | ﹤0.01% |
18,751
-5,825
| -24% | -$321K |
|
1920
IMAX
IMAX
$2.81B
| $1.04M | ﹤0.01% |
57,528
+10,909
| +23% | +$150K |
|
1921
Wabash National
WNC
$510M
| $1.03M | ﹤0.01% |
60,061
-7,267
| -11% | -$118K |
|
1922
OFG Bancorp
OFG
$2.2B
| $1.03M | ﹤0.01% |
55,761
| – | – |
|
1923
Encore Capital Group
ECPG
$2.01B
| $1.03M | ﹤0.01% |
26,535
+3,842
| +17% | +$140K |
|
|
LMNX
1924
DELISTED
Luminex Corp
LMNX
| $1.03M | ﹤0.01% |
44,597
+6,376
| +17% | +$148K |
|
1925
Provident Financial Services
PFS
$3.17B
| $1.03M | ﹤0.01% |
57,238
| – | – |
|
Similar funds
UBS AM's Q4 2020 Portfolio in Review
As of Q4 2020, UBS AM held 2,632 positions worth $213B, up 15% from $186B the previous quarter. Its ten largest holdings account for 23% of the portfolio.
UBS AM's Q4 2020 filing shows 139 new, 1,393 increased, 625 reduced and 83 closed positions. Its largest new stake was Maravai LifeSciences: 3,763,012 shares worth $106M. The largest sale was Mastercard, an estimated $384M.
By sector, the portfolio is most concentrated in Technology at 25% of assets, up from 24% a quarter earlier, followed by Consumer Discretionary and Healthcare.
- UBS AM's largest Q4 2020 buy was Maravai LifeSciences: 3,763,012 shares worth $106M.
- UBS AM added most to Apple in Q4 2020, an estimated $438M increase.
- UBS AM's biggest Q4 2020 reduction was Mastercard, cutting an estimated $384M.
- UBS AM fully exited State Street Technology Select Sector SPDR ETF in Q4 2020, selling an estimated $115M.
- UBS AM's ten largest holdings make up 23% of its $213B portfolio in Q4 2020.
- UBS AM opened 139 new positions and closed 83 in Q4 2020.
- UBS AM's portfolio value rose 15% quarter-over-quarter to $213B.
Based on UBS AM's 13F filing for Q4 2020, filed 17 Feb 2021.